Added to YB: 2026-04-27
Pitch date: 2026-04-23
ERF.PA [neutral]
Eurofins Scientific SE
-0.23%
current return
Author Info
Colubeat Investment Desk writes and shares analysis on exceptional companies with sustainable moats. Sometimes undervalued, always high quality. Sign up for the newsletter.
Company Info
Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide.
Market Cap
EUR 11.0B
Pitch Price
EUR 60.96
Price Target
130.00 (+110%)
Dividend
1.15%
EV/EBITDA
9.08
P/E
28.09
EV/Sales
2.01
Sector
Life Sciences Tools and Services
Category
growth
Update: Eurofins Scientific ($ERF) Q1 2026
ERF.PA (update): Q1 2026 organic growth 2.6% (below mid-single-digit target) due to weather shutdowns (5% revenue loss per 3-day closure), intentional exit of loss-making SYNLAB contracts in Spain/Italy, & -4.8% FX headwind. Margins improved despite soft volume, signaling operational leverage. BioPharma +1.1% (Central Lab contracts still delayed, 3rd consecutive 'H2 start' mention—key monitoring point). Operating CapEx rises €328M→€400M in 2026, delaying FCF expansion 6-12mo (-2pp IRR). €110M Q1 buybacks. Divested E&E Testing to UL at 14x EV/EBITDA vs ERF's 9.7x consensus—40%+ discount to strategic value. Rest of World +8.6% (6th quarter 7.7%-11.7%). €130 PT unchanged; Q3 critical for BioPharma acceleration confirmation.
Read full article (9 min)